Lilly Puts Potential $660M on the Line for Protein-Protein Interaction Blockers

Eli Lilly on Tuesday signed a license and collaboration agreement with Tokyo-based biotech PRISM BioLab to discover and develop small molecule inhibitors of protein-protein interactions.